Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACHE known ✓ | P22303 | 1/20 | 0.32 |
| ▸ | SLC6A3 known ✓ | Q01959 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 1/20 | 0.41 |
| ▸ | EEF2K | O00418 | 1/20 | 0.35 |
| ▸ | IDO1 | P14902 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 2/20 | 0.35 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | CHKA | P35790 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17965484 | 0.98 | CA1 (0.42) | CA1CA2EEF2KIDO1TSHR | |
| SCHEMBL13319085 | 0.80 | SIGMAR1 (0.44) | EEF2KCHKAACHESIGMAR1 | |
| SCHEMBL11347488 | 0.69 | SLC18A3 (0.47) | CA1CA2TSHRSLC18A3ALDH1A1 | |
| Bromide SCHEMBL15993836 | 0.67 | CHKA (0.36) | CA1CA2EEF2KCHKASIGMAR1 | |
| SCHEMBL11347486 | 0.60 | SIGMAR1 (0.72) | TSHRALDH1A1KMT2ASIGMAR1 | |
| SCHEMBL3037947 | 0.60 | SIGMAR1 (0.72) | TSHRALDH1A1KMT2ASIGMAR1 | |
| Perchlorate SCHEMBL11540886 | 0.60 | NPC1 (0.35) | CA1CA2TSHRCHKATDP1 | |
| SCHEMBL6549159 | 0.58 | TP53 (0.46) | IDO1TSHRCHKAALDH1A1MEN1 | |
| SCHEMBL7329630 | 0.58 | SIGMAR1 (0.81) | TSHRSIGMAR1 | |
| SCHEMBL1836416 | 0.58 | LMNA (0.46) | TSHRALDH1A1MEN1KMT2AACHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 248 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240058434-A1 | NANOEMULSION UNIVERSAL INFLUENZA VACCINE | BLUEWILLOW BIOLOGICS, INC. (US) | 2024-02-22 | — | — | US | claimed |
| WO-2023133143-A1 | INTRANASAL POLYSACCHARIDE CONJUGATE NANOEMULSION VACCINES AND METHODS OF USING THE SAME | BLUEWILLOW BIOLOGICS, INC. (US) | 2023-07-13 | — | — | WO | claimed |
| US-20200246449-A1 | INTRAVENOUS IMMUNOGLOBULIN COMPOSITIONS SPECIFIC FOR RESPIRATORY SYNCYTIAL VIRUS AND METHODS OF MAKING AND USING THE SAME | NANOBIO CORPORATION (US) | 2020-08-06 | — | — | US | claimed |
| US-9492525-B2 | Human respiratory syncytial virus vaccine | NANOBIO CORPORATION (US) | 2016-11-15 | — | — | US | claimed |
| EP-2729169-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | Nanobio Corporation (US) | 2014-05-14 | — | — | EP | claimed |
| EP-2545937-A1 | Nanoemulsion vaccines | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2013-01-16 | — | — | EP | claimed |
| US-20130011443-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION | 2013-01-10 | — | — | US | claimed |
| WO-2013006797-A1 | HUMAN RESPIRATORY SYNCYTIAL VIRUS VACCINE | NANOBIO CORPORATION (US) | 2013-01-10 | — | — | WO | claimed |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2012-11-01 | — | — | US | claimed |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION | 2012-08-30 | — | — | US | claimed |
| US-20090304799-A1 | NANOEMULSION INFLUENZA VACCINE | NANOBIO CORPORATION | 2009-12-10 | — | — | US | claimed |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION | 2009-10-29 | — | — | US | claimed |
| WO-2009132342-A1 | NANOEMULSIONS FOR TREATING FUNGAL, YEAST AND MOLD INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009132343-A1 | NANOEMULSIONS FOR TREATING ONCHOMYCOSIS | NANOBIO CORPORATION (US) | 2009-10-29 | — | — | WO | claimed |
| WO-2009129470-A2 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | NANOBIO CORPORATION (US) | 2009-10-22 | — | — | WO | claimed |
| US-20090143476-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| US-20090143477-A1 | Antimicrobial Nanoemulsion Compositions and Methods | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2009-06-04 | — | — | US | claimed |
| US-6559189-B2 | For decontaminating areas, samples, solutions, and foodstuffs colonized or infected by pathogens and microorganisms | REGENTS OF THE UNIVERSITY OF MICHIGAN | 2003-05-06 | — | — | US | claimed |
| US-20020045667-A1 | Non-toxic antimicrobial compositions and methods of use | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2002-04-18 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090269394-A1 | METHODS AND COMPOSITIONS FOR TREATING ONCHOMYCOSIS | DPM1, ERG28, POLR1C | ACHE 3885/4885SLC6A3 4717/4885CA1 3831/4885 |
| US-20090269380-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | ACHE 3312/4885SLC6A3 4796/4885CA1 2808/4885 |
| US-20120219602-A1 | METHODS FOR TREATING HERPES VIRUS INFECTIONS | STING1, IFNG, NGF | ACHE 1247/4885SLC6A3 3040/4885CA1 1340/4885 |
| US-20120276182-A1 | METHODS OF TREATING FUNGAL, YEAST AND MOLD INFECTIONS | DPM1, ERG28, CYP51A1 | ACHE 3312/4885SLC6A3 4796/4885CA1 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.